Jazz PharmaceuticalsJAZZ
Recorded

Jazz Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 3 minParticipants21

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Jazz Pharmaceuticals 2026 third quarter earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you would need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. We do ask you, please, to limit to one question. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to John Bluth, Head of Investor Relations.

John BluthHead of Investor Relations

Please go ahead. Thank you, and good afternoon, everyone.

John BluthHead of Investor Relations

Today, Jazz Pharmaceuticals reported its third quarter 2026 financial results. The slide presentation accompanying this webcast is available on the investor section of our website, along with the press release and quarterly report on Form 10-Q for the quarter ended September 30, 2026. On the call today are Renée Galá, President and Chief Executive Officer, Sam Pearce, Chief Commercial Officer, Rob Iannone, Global Head of R&D and Chief Medical Officer, and Phil Johnson, Chief Financial Officer. On slide 2, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential, and anticipated development, regulatory and commercial milestones, which involve risks and uncertainties that could cause actual events, performance, and results to differ materially from those contained in these forward-looking statements.

John BluthHead of Investor Relations

We encourage you to review these risks and uncertainties described in today's press release and under the caption Risk Factors in our annual report on Form 10-K for the fiscal year ended December 31, 2025, and quarterly report on Form 10-Q for the quarter ended September 30, 2026. We undertake no duty or obligation to update our forward-looking statements. Furthermore, we will discuss non-GAAP financial measures on this webcast. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release and the slide presentation available on the investor section of our website. I'll now turn the call over to Renée.

Renee GalaPresident and CEO

Thank you, John. Good afternoon, everyone, and thank you for joining us today. Our third quarter results demonstrate the progress we are making as we build a more innovative and diversified Jazz. We delivered record revenues of $1.24 billion, an increase of 10% year-over-year, while advancing several important drivers of our future growth. Most notably, the FDA approval and launch of Ziihera in first-line HER2-positive metastatic GEA was a defining milestone for Jazz, establishing an important new source of growth and marking the beginning of what we believe could be a much broader opportunity across HER2-expressing cancers. As you'll hear from Sam, the launch is off to a fantastic start. Longer-term data presented at ESMO further strengthen our conviction in Ziihera, and we continue to see peak sales potential of $3 billion-$5 billion.

Renee GalaPresident and CEO

Our commercial portfolio is performing well, with multiple products contributing to our growth. Oncology revenues grew 35% year over year, driven by the launches of Modeyso and Zepzelca in the first-line maintenance setting, while sustained demand for Xywav continued to underscore its durability and differentiation. Given our third quarter performance, we have increased our 2026 revenue guidance, as Phil will outline later in the call. Our sustained performance and disciplined approach to capital allocation place us in an excellent position to continue investing in our business today while further building new sources of growth for the future. One important example of how we are investing for the future is our acquisition of Actio Biosciences, which we completed during the quarter. This acquisition brings ABS-1230 into the Jazz pipeline and builds on our leadership in rare epilepsy.

Renee GalaPresident and CEO

ABS-1230 is a clinical-stage, novel, small-molecule precision therapy designed to selectively inhibit the KCNT1 ion channel. In early proof-of-concept trials, ABS-1230 demonstrated meaningful seizure reductions that provide a high degree of confidence in the mechanism and molecule. We look forward to presenting initial patient data at a medical meeting this quarter, which we believe will generate shared excitement for the program. As outlined on slide 5, the Actio acquisition illustrates the type of rare disease opportunities we are seeking, highly differentiated assets in areas of significant unmet medical need where we believe Jazz can create meaningful value. The cash flow generated by our commercial portfolio gives us the flexibility to pursue additional opportunities with the same disciplined approach. Before turning the call over to Sam, I want to take a moment to recognize the tremendous contributions she has made to Jazz.

Renee GalaPresident and CEO

Under her leadership, our commercial teams have achieved major milestones, including propelling Epidiolex to blockbuster status, executing key oncology launches, and further establishing our leadership in sleep medicine. Equally important, Sam has built a highly capable commercial leadership team that is driving our performance today and is well-positioned to carry it forward. She will remain with Jazz through the appointment of her successor to support a seamless transition. Sam, we are deeply grateful for your leadership and contributions, and we wish you a wonderful, well-deserved retirement. With that, I'll turn the call over to Sam to review our commercial performance.

Sam PearceChief Commercial Officer

Thank you for those kind words, Renee. It has been an absolute privilege to lead this exceptional commercial team during a transformative period of growth for Jazz. I came into this role looking to accomplish three key things: to drive strong growth in the commercial portfolio, to build out the team's capabilities to ensure long-term success, and to build a high-performing, cohesive leadership team. I can say with certainty that we've achieved all of those things. While I will miss my time at Jazz, and I'm certainly looking forward to my retirement, I will be here to ensure a smooth transition over the coming months. With that, I'll now jump into the quarter. The commercial team delivered another quarter of record revenues. These results reflect our sharp operational focus, which continues to yield commercial momentum across our expanding portfolio, headlined by the outstanding early launch of Ziihera in GEA.

Sam PearceChief Commercial Officer

To kick off our third quarter commercial performance update, I will begin with our rare sleep portfolio on slide seven. Xywav net product sales increased 12% to $483 million. We added approximately 425 net patients in the quarter across narcolepsy and idiopathic hypersomnia, demonstrating the sustained clinical value physicians and patients place on this medicine. We believe that truly addressing rare sleep disorders requires a restorative approach that connects night and day. Recently updated findings from our DUET trial demonstrate Xywav's profound impact on consolidating disrupted nighttime sleep, which directly translates to a meaningful reduction in debilitating daytime symptoms for both narcolepsy and idiopathic hypersomnia patients. These data reinforce Xywav's critical dual role, optimizing sleep architecture overnight to maximize patient functioning during the day. Furthermore, our XYLO study showed that patients switching to this low-sodium formulation achieved a clinically meaningful reduction in blood pressure, reinforcing Xywav's crucial cardiovascular safety profile.

Sam PearceChief Commercial Officer

Our dedication to patient well-being also extends to our best-in-class JazzCares patient services, including our field-based nurse educators. These programs drive patient persistence and ensure appropriate use and long-term adherence to treatments. As the NT1 landscape evolves with the introduction of orexin-2 receptor agonists, we expect there could be near-term extension in the time it takes for some new patients to initiate therapy. However, we expect the clinical value of treating disrupted nighttime sleep to remain a priority for HCPs and patients, and we expect Xywav to remain a foundational therapy across NT1, NT2, and idiopathic hypersomnia. Our payer discussions for 2027 are well underway, positioning us favorably as we head into next year. We have consistently seen throughout 2026 that the low-sodium profile of Xywav is highly valued by physicians, patients, and payers.

Sam PearceChief Commercial Officer

We enter 2027 focused on maintaining this momentum, and we believe the strong clinical differentiation of Xywav will continue to support its durability. Turning to Epidiolex on slide eight, net product sales reached $295 million for the quarter, driven by solid underlying demand. Year-over-year growth was negatively affected by lower gross-to-net deductions in the third quarter of 2025 and lower levels of inventory build this quarter compared to the same quarter last year. A key driver of exceptional patient persistence for Epidiolex is our nurse navigator program within JazzCares. We see a direct correlation between program enrollment and improved treatment adherence. To further support long-term adherence, we are actively generating evidence to underscore Epidiolex's broad benefits beyond seizure control alone. Real-world insights from studies like EpiCom and our BECOME Caregiver Survey highlight meaningful improvements in daily cognitive functioning and reduced caregiver burden.

Sam PearceChief Commercial Officer

Looking ahead, we have several key levers to drive long-term expansion. The FDA has accepted our NDA for a new cannabidiol oral capsule formulation with a PDUFA date of April 16, 2027, which will improve accessibility and compliance for patients, including certain segments of the adult patient population. We are also advancing a clinical trial exploring Epidiolex in developmental and epileptic encephalopathies, as well as our ongoing focal onset seizure trial. Supported by robust patient durability into the very late 2030s, we remain highly confident in Epidiolex's ability to serve a broader patient population. Turning to our oncology portfolio on slide nine, the early launch of Ziihera in GEA is delivering a truly transformative therapy to patients while establishing an expansion opportunity for our oncology business. In the third quarter, Ziihera generated $21 million in net product sales.

Sam PearceChief Commercial Officer

Feedback from key opinion leaders and treating physicians has been exceptional, confirming our belief that Ziihera represents a new HER2-positive backbone therapy in this setting. Our early post-launch market research shows more than three-quarters of HCPs report a high likelihood to prescribe Ziihera for GEA, which signals a positive reaction to our data. Our launch blueprint draws directly on Jazz's core strengths, identifying highly defined specialist patient populations and mobilizing a dedicated commercial infrastructure to serve them efficiently. To help frame the trajectory of the launch and model the uptake curve going forward, I want to highlight two core dynamics. First, our commercial strategy is focused on precisely identifying the specific population of 3,000 to 4,000 annual patients in the U.S. who are eligible to receive Ziihera in this indication.

Sam PearceChief Commercial Officer

Because these patients are distributed across different clinical settings, we are deploying a comprehensive outreach strategy, broadening our reach beyond academic centers to mobilize community accounts where the majority of GEA patients are cared for. Within the first two weeks post-approval, our field teams conducted more than 1,500 clinical interactions with oncologists and patient advocacy partners. This approach has resulted in strong brand awareness. We saw a threefold increase in new account ordering of Ziihera in September compared to August, with the vast majority coming from community accounts. This contributed to an approximately 40% month-over-month increase in average vial demand per selling day. Second, given there is no bolus of expanded access program or clinical trial patients waiting to transition to commercial drug, the demand we are seeing reflects new patient starts as community centers integrate this practice-changing regimen into their treatment protocols.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day